{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-019852","form_type":"8-K","ticker":"CELC","cik":"0001603454","company_name":"Celcuity Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.176900+00:00","generated_at":"2026-06-01T23:07:04.204002+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Celcuity Q1 net loss $21.6M; Phase 3 VIKTORIA-1 on track for H2 2024 data","bullets":["Net loss $21.6M ($0.64/sh) vs $11.9M ($0.55/sh) in Q1 2023; cash $177.7M expected runway into H1 2026.","Phase 3 VIKTORIA-1 on track: topline PIK3CA wild-type data H2 2024; mutant sub-group H1 2025.","First patient dosed in Phase 1b/2 trial of gedatolisib + darolutamide for mCRPC; prelim data expected H1 2025.","Appointed Eldon Mayer as CCO in Feb 2024 to prepare for potential gedatolisib launch.","R&D expenses $20.7M (up $9.4M YoY) driven by VIKTORIA-1 and new trial initiation."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-019852","json":"https://secwatch.observer/filing/0001493152-24-019852.json","markdown":"https://secwatch.observer/filing/0001493152-24-019852.md","text":"https://secwatch.observer/filing/0001493152-24-019852.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1603454/000149315224019852/0001493152-24-019852-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1603454/000149315224019852/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:07:04.204002+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6b80931be6781a652bf24fc80e5121f1c3dea259","claim":"Celcuity Inc. reported the first quarter ended March 31, 2024 results: net income Net loss for the first quarter of 2024 was $21.6 million, or $0.64 loss per share, EPS $0.64 loss per share.","evidence_excerpt":"Celcuity Inc. (the “Company”) issued a press release regarding the Company’s financial results for the first quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1603454/000149315224019852/0001493152-24-019852-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Net income","value":"Net loss for the first quarter of 2024 was $21.6 million, or $0.64 loss per share"},{"label":"EPS","value":"$0.64 loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}